Sinopharm (01099) reported that, as of November 30, 2025, its total authorized/registered share capital remained RMB 3,120,656,191. The company’s H Shares and Domestic Shares stood unchanged at 1,341,810,740 shares and 1,778,845,451 shares, respectively, with no treasury shares recorded.

The announcement indicated no changes in share options, warrants, convertibles, or other agreements to issue shares. It also noted that, as Sinopharm is incorporated in the People’s Republic of China, the concept of “authorized share capital” is not applicable.